Research.Patient.info

High-Risk, Surgically Resectable Melanoma research hub

1 indexed studies · 0 currently recruiting

authorisedHuman Pharmacology (Phase I)- Other
A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT
This study is for people in the UK with a type of skin cancer called high-risk melanoma that can be removed by surgery. It's testing new combinations of medicines (immunotherapy plus other drugs) before surgery to see if they can shrink the cancer and stop it from coming back.
Italy